Clinical Trial Update: Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update sponsored by Regeneron Pharmaceuticals to evaluate stroke and systemic embolism prevention in adults with atrial fibrillation wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atrial Fibrillation (AF) | Phase 3 | Status: NOT_YET_RECRUITING